Medical Science Liaison Job Description

A Medical Science Liaison is a field-based scientist employed by a drug, biotech, diagnostics or device company to hold peer-level scientific conversations with physicians, pharmacists, nurse practitioners and researchers. The job belongs to medical affairs, not the commercial organization, and its working material is evidence: trial results, mechanism of action, safety signals, real-world data and the open questions a product's evidence has not yet answered. The Medical Science Liaison Society traces the role to Upjohn Pharmaceuticals, which established it in 1967 to put scientifically trained staff in the field.

A working week mixes visits to academic medical centers and community practices with video calls, congress preparation and internal meetings with medical directors, clinical operations and publication planners. The MSL Society's 2025 USA survey asked US respondents in MSL, Sr. MSL and Medical Advisor roles which activities they take part in. KOL relationship management was named by 98%, responding to medical information requests by 82%, supporting investigator-led research such as IITs and ISTs by 74%, and training and supporting the sales force by 67%. That last number is a reminder that medical and commercial teams do work together; what keeps them apart is content, with scientific exchange kept separate from promotion.

Territory size shapes the job. In the same survey, the average US MSL territory spanned 8 states. At large pharmaceutical and biotech companies the average was 5 states, while MSLs at medical device companies averaged 27. A wide territory means flights, rental cars and hotel nights; a tight one means repeat visits to the same cancer centers, rheumatology groups or transplant programs.

Federal guidance shapes scientific exchange. In January 2025, FDA issued final guidance titled "Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products: Questions and Answers." It describes FDA's enforcement policy for firm-initiated communications of scientific information on unapproved uses, says those communications should be separate from promotional communications about approved uses, and recommends that the personnel who share them have specialized training. The document is labeled as nonbinding recommendations, and FDA's guidance page says it is not for current implementation, pending the Office of Management and Budget's decision on its collection of information. Questions a physician raises without prompting are addressed in a separate December 2011 draft guidance on unsolicited requests, which the January 2025 document cites. Day to day, the work runs on slide decks cleared through medical, legal and regulatory review, interaction notes logged in a CRM, and formal requests routed to the medical information team.

The other half of the job runs in reverse. An MSL listens for what a hematologist thinks of a competitor's dosing schedule, why a community oncologist has not ordered a new biomarker test, or which patients a trial's eligibility criteria leave out. Those observations are written up as field insights for the medical strategy team. Congress weeks compress all of it into a few days of data readouts, expert meetings and follow-up requests.

The degree picture is clear in the MSL Society's 2025 USA survey. By highest degree, US respondents in MSL, Sr. MSL and Medical Advisor roles broke down as PharmD 43%, PhD 33%, master's degree 9%, other doctorates such as DNP or OD 8%, MD, DO or MBBS 4%, and bachelor's degree 1%. A candidate without a doctorate is not shut out, but should expect to compete on therapeutic-area depth and clinical credibility.

Entry routes differ by degree. PharmD graduates can enter through a post-graduate industry fellowship in medical affairs or after a clinical residency and a few years of specialty practice. PhD scientists typically come from a postdoc or a faculty position in the disease area they will cover, which gives them the publication record and conference network that experts respect. Nurse practitioners, physician assistants and physicians bring patient-management judgment that matters in areas such as oncology, neurology and rare disease, where treatment decisions are nuanced. Medical information specialists, clinical research associates and medical writers can also move into the field once they have strong therapeutic-area knowledge.

As a rough guide, 2 to 5 years of clinical practice, research or medical information work in the target therapeutic area gives a candidate a credible story for a first MSL interview. The skills worth building before applying:

• Critical appraisal. Reading a Phase 3 paper for endpoint choice, hazard ratios, censoring, subgroup analyses and what the confidence intervals actually allow anyone to claim.
• Presenting to skeptics. Walking a department chair through a data set in 20 minutes and handling hostile questions without overstating the evidence.
• Insight writing. Turning a 45-minute conversation into a four-line insight that a medical director can act on.
• Compliance fluency. Knowing the difference between proactive and reactive exchange, when to route a question to medical information, and how to document an interaction.
• Territory discipline. Planning visits, managing a CRM and a travel budget, and keeping a clean driving record when a company car comes with the job.

Two credentials target the field. The Medical Science Liaison Board Certification (MSL-BC) is awarded by the Medical Science Liaison Society. Its eligibility rules call for a bachelor's degree or higher and one year of cumulative full-time experience working as an MSL or leading an MSL team, so aspiring MSLs cannot sit for it; the Society describes it as not required and optional. The Board Certified Medical Affairs Specialist (BCMAS) program is run by the Accreditation Council for Medical Affairs. Clinicians who hold a license, such as a state pharmacist, nursing or medical license, can keep it active, which preserves the option of returning to practice and adds credibility with prescribers.

Pay in the field climbs steadily with tenure. In the MSL Society's 2025 USA survey, median salary for US MSL, Sr. MSL and Medical Advisor respondents was $177,000 for those with less than one year in the function, $195,000 at 2 to 4 years, $234,000 at 8 to 10 years and $238,000 beyond 15 years. Company type matters too: the median was $210,000 at small pharmaceutical and biotech companies (revenue under $1 billion), $206,000 at large ones (revenue of $10 billion or more), $180,000 at medical device makers and $176,000 at diagnostic companies. Asked about raises, 44% reported a 3% to 4% base salary increase in the prior 12 months. The survey was open from September 11 to December 12, recruited through LinkedIn groups, the Society's own channels and direct contacts, and its results were not weighted, so treat it as a benchmark rather than a census.

Federal statistics do not track the title on its own. O*NET lists "Medical Science Liaison (MSL)" as an alternate title under Medical Scientists, Except Epidemiologists (SOC 19-1042), and projects that occupation's growth for 2025 to 2035 as much faster than average (7% or higher), with about 10,500 openings a year on average. That projection covers the whole occupation, including laboratory and clinical researchers, so it is context rather than a forecast for MSL jobs.

Job security deserves a close look. When the survey asked the primary reason for leaving their most recent MSL position, 8% of US MSL respondents said they were terminated or laid off and 7% cited a company buyout, reorganization or downsizing; 41% were still in their first MSL role. Because field medical teams are built around specific products and therapeutic areas, candidates weighing an offer can reasonably ask how long the team has existed, what the pipeline's next data readouts are, and how the team fared in the last reorganization.

AI has already reached the field. In the same survey, 42% of US MSL respondents said they use AI tools in their role regularly, 46% occasionally and 11% not at all. AI tools can summarize new publications before a visit, draft call notes and sort field insights by theme. None of that removes the need for an MSL to answer a pointed question about a subgroup analysis in real time.

Transparency rules also shape the work. CMS runs Open Payments, a national disclosure program with a public database of payments that drug and device companies make to covered recipients such as physicians. Its Program Year 2025 data, covering January 1 to December 31, 2025, includes 17.07 million published records totaling $14.67 billion. An MSL who hosts an expert lunch or arranges an advisory board honorarium is generating a record that may end up in that database.

The ladder runs from MSL to Senior MSL, then to MSL manager or regional director, and on to medical director, head of field medical or a medical affairs strategy role at headquarters. MSL Excellence or Operations, which runs training, metrics and systems for field teams, is a separate track for MSLs who prefer building programs to covering a territory.

Dear Dr. Ramirez,

I am applying for the Medical Science Liaison position covering the Mountain West on your hematology team. I am a PharmD with a PGY2 residency in oncology pharmacy and four years as the hematology clinical pharmacist at a regional cancer center, where I sat on the pharmacy and therapeutics committee and helped write our bispecific antibody order sets.

Much of my current job already looks like scientific exchange. When a new CAR-T or bispecific product reaches our formulary review, I build the evidence summary: the pivotal trial design, response rates by prior line of therapy, cytokine release syndrome grading, and the monitoring burden it places on our infusion center. I then present it to hematologists who have read the same paper and want to argue about the control arm. I have learned to say "the data do not answer that yet" without losing the room.

I also know what community physicians in this territory are dealing with. Our center refers patients to two academic programs in the region, and I coordinate the handoffs for patients who need cellular therapy. I can tell you which practices struggle with toxicity management after discharge, and which questions come up again and again from oncologists who see these patients only once a year.

I want to move into medical affairs because I enjoy the evidence conversation more than the dispensing logistics, and because I think field insights from people who have managed these patients at the bedside make a company's medical strategy better. I am comfortable with heavy travel, with documenting every interaction carefully, and with the discipline of answering only what was asked.

I would welcome the chance to walk you through one of my formulary reviews.

Sincerely, Jordan Ellison, PharmD, BCOP